Compare EVI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVI | TECX |
|---|---|---|
| Founded | 1959 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.9M | 393.0M |
| IPO Year | 1995 | N/A |
| Metric | EVI | TECX |
|---|---|---|
| Price | $20.60 | $29.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $35.00 | ★ $80.40 |
| AVG Volume (30 Days) | 23.9K | ★ 317.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $389,830,000.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | $78.44 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $14.99 | $13.70 |
| 52 Week High | $34.82 | $35.99 |
| Indicator | EVI | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 54.75 |
| Support Level | $20.54 | $16.83 |
| Resistance Level | $21.40 | $35.99 |
| Average True Range (ATR) | 1.24 | 2.73 |
| MACD | 0.34 | -0.42 |
| Stochastic Oscillator | 76.92 | 48.43 |
EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.